New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
07:40 EDTSNY, POZNPOZEN says reduced R&D staff, other costs as part of controlling expenses
POZEN (POZN) said, "For FY14, the company’s areas of strategic focus are obtaining FDA approval for PA8140/PA32540, transitioning all licensed know-how relating to PA8140/PA32540 in the U.S. and fulfilling all contractual obligations to Sanofi (SNY) U.S., completing study PA10040-102, an additional Phase 1 pharmacodynamics study, preparing the regulatory filing document for PA product candidates in the European Union, finding partners for the PA asset in ex-U.S. territories, and controlling expenses. As part of controlling expenses, we have reduced our R&D staff and other costs and in the future will continue to reduce staff not required to support our ongoing business activities. Our board of directors and management team continue to explore potential ways to return value to our shareholders, including future cash distributions when we accumulate surplus cash as a result of receiving milestones and royalties from our commercial partners."
News For POZN;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
05:23 EDTSNYSanofi, Regeneron announce Praluent ODYSSEY OUTCOMES trial enrollment complete
Subscribe for More Information
November 23, 2015
09:07 EDTPOZNPOZEN, Tribute provide update on pending combination
POZEN and Tribute Pharmaceuticals Canada provided an update on their pending combination transactions. The companies have reviewed the recent guidance from the U.S. Treasury's Notice 2015-79 issued on November 19 and its potential impact on the proposed transaction. POZEN and Tribute remain committed to combining their respective businesses and are considering a Canadian domicile for Aralez Pharmaceuticals, the new parent entity for the combined companies. With the planned business operations in Ireland, Canada and the United States, the Canadian domicile offers substantially similar financial, tax and competitive advantages to an Irish domicile, and will benefit from Tribute's business foundation and strong presence in Canada where Tribute was incorporated and from where it has always operated. The parties further believe that a Canadian domicile will be in compliance with the new Treasury Department Guidance and are working diligently and expeditiously on an alternative transaction structure that would be in the best interest of their respective securityholders, and the parties are further considering the Treasury Department Guidance as they continue to arrive at this alternative transaction structure.
November 20, 2015
06:09 EDTSNYSanofi, AstraZeneca to exchange more than 210,000 compounds
Subscribe for More Information
November 19, 2015
10:11 EDTPOZNHigh option volume stocks
November 18, 2015
08:11 EDTSNYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use